Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Amubarvimab · BRII-196

Monoclonal antibody · Antagonist of SARS-CoV-2 spike protein · developed by Brii Biosciences

Phase 2/3 Most advanced trial (none active)
2 Registered trials

What is Amubarvimab?

Amubarvimab is a neutralizing human monoclonal antibody directed against the spike protein of SARS-CoV-2. It binds a conserved epitope on the spike protein, blocking viral attachment and entry into human cells. It is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BRII-196
Drug type
Monoclonal antibody
Targets
SARS-CoV-2 spike protein
Mechanism
Antagonist of SARS-CoV-2 spike protein
Pathways
viral attachment and entry into human cells
Therapy area
Infectious disease
Developer
Brii Biosciences Limited
In trials of
SABS, VIR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
2AD5KH3SE4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04518410 Phase 2/3 Coronavirus Completed SABS
NCT04501978 Phase 3 Covid19 Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoronavirusCovid19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.